until the US regulator cleared Apellis' complement C3 inhibitor Syfovre (pegcetacoplan) in 2023. That was followed shortly after by the FDA approval of Astellas' C5 inhibitor Izervay (avacincaptad ...

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Astellas Pharma (ALPMF – Research Report), with a price target of Yen1,700.00. The company’s shares ...

With the power of robotics and the personalized medicine expertise of one of Japan's top drugmakers, Astellas Pharma and ...

Astellas and Yaskawa are establishing a joint venture for the development of a cell therapy product manufacturing platform ...

Astellas Pharma and Yaskawa Electric have signed a definitive agreement to establish a joint venture aimed at advancing cell therapy manufacturing through automation. According to Astellas, the ...

The agreement—powered by YASKAWA's Maholo robot—aims to address challenges in production and commercialization while offering ...

NORTHBROOK, Ill., Feb. 27, 2025 /PRNewswire/ -- Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas"), and MBC BioLabs, a premier launchpad for ...

Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and safety of PADCEV, or enfortumab vedotin-ejfv, a Nectin-4 ...

Feb. 27, 2025 /PRNewswire/ -- Astellas Pharma U.S. Inc. (Head of Commercial ... and service that you use and your relationship with us. We may use it to: Verify your identity, personalize the ...

Astellas Pharma Inc., a global life sciences company, announced the US Food and Drug Administration (FDA) approved expanded US Prescribing information for Izervay (avacincaptad pegol intravitreal ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...